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Abstract
Interpreting variants, especially noncoding ones, in the increasing number of personal genomes is
challenging. We used patterns of polymorphisms in functionally annotated regions in 1092
humans to identify deleterious variants; then we experimentally validated candidates. We analyzed
both coding and noncoding regions, with the former corroborating the latter. We found regions
particularly sensitive to mutations (“ultrasensitive”) and variants that are disruptive because of
mechanistic effects on transcription-factor binding (that is, “motif-breakers”). We also found
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variants in regions with higher network centrality tend to be deleterious. Insertions and deletions
followed a similar pattern to single-nucleotide variants, with some notable exceptions (e.g., certain
deletions and enhancers). On the basis of these patterns, we developed a computational tool
(FunSeq), whose application to ~90 cancer genomes reveals nearly a hundred candidate noncoding
drivers.
Whole-genome sequencing has revealed millions of variants per individual. However, the
functional implications of the vast majority of these variants remain poorly understood (1).
It is well established that variants in protein-coding genes play a crucial role in human
disease. Although it is known that noncoding regions are under negative selection and that
variants in them have been linked to disease, their role is generally less well understood
(2-9).
In particular, whereas some studies have demonstrated a link between common variants
from genome-wide association studies (GWASs) and regulatory regions (2, 3), the
deleterious effects of rare inherited variants and somatic cancer mutations in noncoding
regions have not been explored in a genome-wide fashion. Recently, three studies reported
noncoding driver mutations in the TERT promoter in multiple tumor types, including
melanomas and gliomas (10-12). In light of these studies and the growing availability of
whole-genome cancer sequencing (13-20), an integrated framework facilitating functional
interpretation of noncoding variants would be useful.
One may think to identify noncoding regions under strong selection purely through
mammalian sequence conservation, and ultraconserved elements have been found in this
fashion (21). However, signatures of purifying selection identified by using population-
variation data could provide better insights into the importance of a genomic region in
humans than evolutionary conservation. This is because many regions of the genome show
human-specific purifying selection, whereas other regions conserved across mammals show
a lack of functional activity and selection in humans (7). Thus, identifying the specific
elements under particularly strong purifying selection among humans could provide novel
insights.
Besides single-nucleotide polymorphisms (SNPs), the human genome also contains other
variants, including small insertions and deletions (indels) and larger structural variants (SVs)
(22). They account for more nucleotide differences among humans than SNPs; hence, an
understanding of their relationship with functional elements is crucial (23).
We used the full range of sequence polymorphisms (ranging from SNPs to SVs) from 1092
humans to study patterns of selection in various functional categories, especially noncoding
regulatory regions (24). We identified specific genomic regions where variants are more
likely to have strong phenotypic impact. The list of these regions includes groups of coding
genes and specific sites within them and, importantly, particular noncoding elements. By
further comparing patterns of polymorphisms with somatic mutations, we show how this list
can aid in the identification of cancer drivers. We used multiple experimental methods for
validation, including yeast two-hybrid experiments, Sanger sequencing of independent
cancer samples, and relevant gene-expression measurements. Furthermore, we provide a
software tool that allows researchers to prioritize noncoding variants in disease studies.
Genomic Elements Under Strong Purifying Selection: Ultrasensitive
Regions
Enrichment of rare variants can be used to estimate the strength of purifying selection in
different functional categories (24). As expected, we found that having variants from 1092
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individuals allowed us to detect specific functional categories under strong purifying
selection with greater power than previously possible (2, 7, 9). In particular, the increased
number of samples provided a better estimate of allele frequencies, making possible the
measurement of differential selective constraints between specific categories [e.g., between
motifs of transcription-factor (TF) families HMG and MADs box] (figs. S4 and S5).
Estimates of purifying selection obtained by using enrichment of rare nonsynonymous SNPs
(derived allele frequency or DAF < 0.5%) showed that different gene categories exhibit
differential selection consistent with their known phenotypic consequences (data S1). Genes
tolerant of loss-of-function (LoF) mutations are under the weakest selection, whereas
cancer-causal genes are under the strongest (Fig. 1A and table S1). GWAS genes associated
with complex disorders lie in between these extremes, consistent with the presence of
common genetic variants in them.
We then analyzed selective constraints in noncoding regions, trying to find elements under
very strong selection (i.e., with a fraction of rare variants similar to that of coding genes,
~67%). We first estimated the strength of negative selection in broad categories [e.g., in all
TF binding sites (TFBSs), deoxyribonuclease I (DNaseI)-hypersensitive sites (DHSs),
noncoding RNAs (ncRNAs), and enhancers] (Fig. 2A). As observed previously, most of
these categories show slight but statistically significant enrichment of rare SNPs compared
with the genomic average; in contrast, pseudogenes demonstrate a depletion (Fig. 2A and
data S2) (2).
We further divided the broad categories into 677 high-resolution ones. These span various
genomic features likely to influence the extent of selection acting on the element. For
example, TFBSs of different TF families are divided into proximal versus distal and cell-
line–specific versus–nonspecific (fig. S7). We find heterogeneous degrees of negative
selection for specific categories (Fig. 2B and data S2). For instance, core motifs in the
binding sites of TF families HMG and Forkhead are under particularly strong selection,
whereas those in the CBF-NFY family do not exhibit selective constraints (relative to the
genomic average) (Fig. 2B). Among all the pseudogenes, polymorphic ones have the highest
fraction of rare alleles, consistent with their functional coding roles in some individuals (25).
Overall, we found that 102 of the 677 categories show statistically significant selective
constraints (data S2) (figs. S8 to S10).
Among these 102 categories, we defined the top ones covering ~0.02% and ~0.4% of the
genome as ultrasensitive and sensitive, respectively (fig. S11) (data S3). Thus, these regions
were defined such that they possess a high fraction of rare variants comparable to that for
coding sequences (67.2% for coding and 65.7% for ultrasensitive) (Fig. 2C). We validated
the rare variants in them by comparison with Complete Genomics data. Sensitive regions
include binding sites of some chromatin and general TFs (e.g., BRF1 and FAM48A) and core
motifs of some important TF families (e.g., JUN, HMG, Forkhead, and GATA). For some
TFs, there is a strong difference between proximal and distal binding sites—for example, for
ZNF274, proximal binding sites are under strong selection and belong to the ultrasensitive
category, whereas distal sites are not under negative selection.
In order to validate the functional importance of sensitive and ultrasensitive regions, we
examined the presence of inherited disease-causing mutations from HGMD (Human Gene
Mutation Database) in them (26). We found ~40- and ~400-fold enrichment of disease-
causing mutations in sensitive and ultrasensitive regions, respectively (compared with the
entire noncoding sequence, P < 2.2 × 10−16) (Fig. 2E). Thus, these documented disease-
causing variants provide independent validation for the functional importance of sensitive
regions. As a specific example, the disease congenital erythropoietic porphyria is caused by
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disruption of a binding site classified as sensitive (the GATA1 motif upstream of
uroporphyrinogen-III synthase) (27). Similarly, the well-known disease-causing ncRNA
RMRP is in the binding site of BRF2, classified as ultrasensitive (28).
Purifying Selection and Other Aspects of Regulatory Regions
We analyzed sites at which SNPs break or conserve core-binding motifs. As expected, we
found that disruptive motif-breaking SNPs are significantly enriched for rare alleles
compared with motif-conserving ones (P < 2.2 × 10−16; Fig. 2D; a motif-breaking SNP is
defined as a change that decreases the matching score in the motif position weight matrix).
This result is over all TF families; moreover, we find the difference between constraints on
motif-breaking versus -conserving SNPs varies considerably for different TF families,
possibly reflecting differences in the topology of their DNA binding domains (data S4).
We also found that expression quantitative trait loci (eQTLs) are enriched in the binding
sites of many TF families (Fig. 2B); the association of TF binding and gene expression at
these loci provides a plausible explanation for their phenotypic effects.
An analysis of SNPs from a personal genome (NA12878) exhibiting allele-specific TF
binding in chromatin immunoprecipitation sequencing (ChIP-Seq) data or allele-specific
expression in RNA-seq data (with the allele-specific “activity” tagging a difference between
maternal and paternal chromosomes at the genomic region in question) showed that these
sites are depleted for rare variants (relative to a matched control) (Fig. 2F). This suggests
that regions where differential allelic activity is not observed may be under stronger
purifying selection (29).
In a similar fashion, we found that core-motif regions bound in a “ubiquitous manner” (i.e.,
where differential cell-type-specific binding is not observed) are under stronger selection
than those bound by TFs in a single cell line (data S2), consistent with the greater functional
importance of ubiquitously bound regions. In relation to this, we further examined how
selective constraints vary among coding genes and DHSs with tissue-specific activity (Fig.
1B). We found there are pronounced differences between tissues: For example, genes with
ovary- and brain-specific expression are under significantly stronger selection than the
average across all tissues (Fig. 1B and table S4). Similarly, some DHSs are under
significantly stronger selection, whereas others are under relaxed constraints relative to the
average (brain- and kidney-specific versus urothelium- and breast-specific, respectively; Fig.
1B and table S4). Last, matched expression and DHS data for six tissues indicate that
purifying selection in tissue-specific genes and their corresponding regulatory regions is
likely correlated (fig S15). Thus, our results suggest that the deleteriousness of both coding
and regulatory variants depends on the tissues they affect.
Purifying Selection in the Interactome and Regulome
We found a significant positive correlation between the fraction of rare SNPs and the degree
centrality of genes in networks: physical protein-protein interaction (PPI) (rho = 0.15; P <
2.2 × 10−16) and regulatory (rho = 0.07; P = 6.8 × 10−08). Thus, consistent with previous
studies, we found that hub genes tend to be under stronger negative selection (29-31).
Indeed, centralities of different gene categories in the PPI network follow the same trend as
differential selective constraints on them: Cancer-causal genes show the highest
connectivity, and LoF-tolerant genes, the least, with GWAS genes in the middle (Figs. 1A
and 3A). These results indicate that the interactions of a gene likely influence the selection
acting on it.
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Hub proteins tend to have more interaction interfaces in the PPI network (31). A corollary of
this is that interaction interfaces are themselves under strong selection, in turn leading to
stronger constraints on hub proteins. Indeed, we found that SNPs disrupting interaction
interfaces are enriched for rare alleles (P < 2.2 × 10−16) (Fig. 3B). To further corroborate
this, we tested a specific case, the Wiskott-Aldrich syndrome protein (WASP), using yeast
two-hybrid (Y2H) experiments (32). All of the three tested single-nucleotide variants
(SNVs) at WASP interaction interfaces disrupted its interactions with other proteins (Fig.
3C). We observed similar behavior for two other proteins: Mutations at their interfaces
disrupted specific protein interactions (fig. S16).
Relationship of Functional Elements with Indels and Larger SVs
We analyzed the association of functional annotations with small indels [<50 base pairs
(bp)] and large SVs (deletions). Similar to the results for nonsynonymous SNPs, we found
that genes linked with diseases show stronger selection against indels whereas LoF-tolerant
genes show weaker constraints (relative to all genes), with a consistent trend for indels
overall and frame-shift indels, in particular (Fig. 4A, fig. S17, and table S1).
The wide range of SV sizes (~50 bp to ~1 Mb) leads to their diverse modes of intersection
with functional elements; for example, a single SV breakpoint can split an element, a
smaller SV can cut out a portion of a single element, and a large SV can engulf an entire
element. To analyze the diverse effects of SVs, we computed the enrichment or depletion of
SVs overlapping each functional category relative to a randomized control. As expected, we
found that genic regions [coding sequences, untranslated regions (UTRs), and introns] are
depleted for SVs, suggesting SVs affecting gene function are deleterious (Fig. 4B) (22).
However, when we broke down the mode of SV intersection with genes into partial versus
whole (an SV breakpoint splitting a gene versus an SV engulfing a whole gene), we
unexpectedly found that SVs are enriched for whole-but depleted for partial-gene overlap.
This suggests that partial-gene overlap is under stronger selection than whole-gene overlap,
possibly because whole-gene deletions may be compensated by duplications. Furthermore,
another category of gene-related elements, pseudogenes, are enriched for SVs, consistent
with their formation mechanism involving either duplication or retrotransposition.
In relation to nongenic elements, we found that SVs tend to be depleted in regulatory
elements such as binding-site motifs and enhancers (Fig. 4B), consistent with our
expectations from SNPs. However, enhancer elements are enriched for SVs formed by
nonallelic homologous recombination (NAHR). This observation is further supported by the
high signal of activating histone marks associated with enhancers (e.g., H3K4me1) around
NAHR breakpoints (Fig. 4C and fig. S18). The association of enhancers and NAHR
deletions may be explained by the three-dimensional structure of chromatin bringing
enhancer elements into close proximity with the gene transcription start site (via DNA
“looping”). If these two “nonallelic” loci contain homologous sequences, it would be
favorable for NAHR to occur.
Functional Implications of Positive Selection Among Human Populations
Negative selection is widespread in the genome; nevertheless, some positions within
negatively selected regions also experience positive selection (33-36). We have previously
identified and validated one category of variants that are strong candidates for positive
selection: sites where continental populations show extreme differences in DAF (HighD
sites) (24). By analyzing these HighD sites, we are focusing on positive selection under the
classic selective-sweep model (37). Positive selection via other modes (such as selection on
standing variation) likely also played a major role in recent human evolution (38).
Khurana et al. Page 6













Nonetheless, functional annotation of HighD sites can provide important insights about
recent adaptations (39).
We examined positive selection in the same fashion as we have done for negative selection:
in coding genes, noncoding regulatory elements, and networks of gene interactions. The
functional analysis of positive selection using highly differentiated sites is limited to SNPs,
because of the low numbers of such indels and SVs in functional elements.
We observed enrichment of HighD sites in UTRs and missense SNPs in coding regions (Fig.
5A). Next, we observed that some disease gene groups (Online Mendelian Inheritance in
Man, HGMD, and GWAS) are enriched for HighD SNPs (fig. S20). Mutations in disease
genes are likely to have strong phenotypic impact; thus, it is possible that some of these
mutations confer advantage for local adaptation. For example, whereas LoF mutations in
ABCA12 lead to the severe skin disorder harlequin ichthyosis (40), we found that a SNP
within the second intron of this gene is a HighD site (DAF > 90% in Europe and East Asia;
13% in Africa), possibly reflecting adaptations of the skin to levels of sunlight outside of
Africa.
Similar to our analysis of negative selection, we analyzed the enrichment of HighD sites in
broad and specific noncoding categories, finding significant enrichment in many noncoding
categories (Fig. 5A). These enriched categories include DHSs (particularly distal ones) and
binding sites of sequence-specific TFs (specifically those in ZNF and NR families). Out of
the seven enriched categories, five are also under significant negative selection (Figs. 2A
and 5A and data S2). Thus, even though an entire category might be under negative
selection, some particular sites within it can be targets of positive selection. In this respect,
our results are consistent with previous studies for missense SNPs: Overall they are under
strong negative selection, but a small group of them have been targets of positive selection
(36).
We found that, as expected, coding genes with HighD SNPs tend to have lower degree
centrality in both PPI and regulatory networks (although the small number of these cases
does not produce statistical significance) (Fig. 5B and fig. S21) (41). In an opposite trend to
genes (where positive selection occurs on the network periphery), HighD sites in TFBSs
tend to occur in hub promoters (P = 0.02 with 23 promoters and P = 3.2 × 10−03 with37
proximal TFBSs) (Fig. 5B). It was previously proposed that mutations in cis elements in
regulatory networks may play an important role in development (42, 43); our study supports
this by suggesting that some hub promoters may have undergone recent adaptive evolution.
Contrasting Patterns of Somatic Mutations with Inherited Variants
After analyzing inherited polymorphisms in functional elements, we examined somatic
variants. Because somatic variants from diverse tumors exhibit different sets of properties,
we analyzed variants from a wide range of cancer types: prostate, breast, and
medulloblastoma (17, 19, 20). We found that ~99% of somatic SNVs occur in noncoding
regions, including TFBSs, ncRNAs, and pseudogenes (fig. S22).
Analysis of matched tumor and normal tissues from the same individuals showed that
somatic variants tend to be enriched for missense (~5×), LoF (~14×), sensitive (~1.2×), and
ultrasensitive (~2×) variants (Fig. 6A, fig. S24, and table S6). Consistent with this trend, we
found higher TF-motif-breaking/conserving ratios for somatic variants compared with
germline ones across many different samples and cancer types (~3 for somatic versus ~1.4
for germline) (Fig. 6B and table S7). Thus, somatic-cancer variants are generally enriched
for functionally deleterious mutations.
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This enrichment of functionally deleterious mutations among somatic variants is
understandable because they are not under organism-level natural selection (unlike
inherited-disease mutations, including GWAS variants). Indeed, among all somatic
mutations, those most deviating from patterns of natural polymorphisms are the most likely
to be cancer drivers. Consistent with this, our analysis has shown that, among all disease
mutations, those causing cancer occur in genes under strongest negative selection (and with
highest network connectivity) (Figs. 1A and 3A). Thus, we argue that somatic variants in the
noncoding elements under strongest selection are the most likely to be cancer drivers.
Another feature of somatic mutations associated with their potential role as drivers is their
recurrence in the same genomic element across multiple cancer samples. We found that
some noncoding elements from our functional categories show recurrent mutations (fig.
S23). For example, the pseudogene RP5-857K21.6 is mutated in three out of seven prostate
cancer samples, and the promoter of RP1 is mutated in two (17).
FunSeq: Tool for Identification of Candidate Drivers in Tumor Genomes
On the basis of the integrative analysis above, we developed a tool to filter somatic variants
from tumor genomes and obtain a short list of candidate driver mutations
(funseq.gersteinlab.org). FunSeq first filters mutations overlapping 1000 Genomes variants
and then prioritizes those in regions under strong selection (sensitive and ultrasensitive),
breaking TF motifs, and those associated with hubs. It can score the deleterious potential of
variants in single or multiple genomes and output the results in easy-to-use formats (i.e.,
“decorated” variant call format files, fig. S29 and data S6). The scores for each noncoding
variant vary from 0 to 6, with 6 corresponding to maximum deleterious effect. When
multiple tumor genomes are given as input, FunSeq also identifies recurrent mutations in the
same element. Although our emphasis is on noncoding variants, it also outputs scores for
coding variants.
We demonstrate the application of FunSeq as a workflow on representative breast and
prostate cancer genomes (Fig. 6C). In the breast cancer sample, the workflow yielded one
noncoding SNV likely to have strong phenotypic consequences: This SNV (i) occurs in an
ultrasensitive region (BRF2 binding site); (ii) breaks a PAX-5 TF binding motif; (iii) is
associated with a network hub (44); and (iv) is recurrent—that is, the regulatory module
contains somatic mutations in multiple breast-cancer samples. In a similar fashion, the
prostate-cancer sample revealed two noncoding SNVs predicted to have strong functional
consequences (Fig. 6C). One of these is in an ultrasensitive region (FAM48A binding site)
and lies in the promoter of WDR74 gene (a hub in the PPI network with degree centrality =
56). We further tested the presence of mutations in this binding site by polymerase chain
reaction followed by Sanger sequencing in an independent cohort of 19 prostate-cancer
samples (45). We found that one sample in the cohort also harbors mutations in this region
(Fig. 6D and fig. S25). Furthermore, we also observed increased expression of WDR74 in
the tumor relative to benign samples (fig. S26). These experimental results provide support
for a likely functional role of this candidate driver.
A large-scale application of our tool to three medulloblastoma, 21 breast, and 64 prostate
cancer genomes provided a total of 98 noncoding candidate drivers (table S8 and data S6)
(17-20). Among these candidates, 68 occur in sensitive regions, 55 break TF motifs, and 90
target network hubs.
Generalized Identification of Deleterious Variants in Personal Genomes
Although we envision the most effective use of our tool for tumor genomes, it can also be
applied to germline sequences to identify potentially deleterious variants. We applied it to
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four personal genomes: Snyder, Venter, NA12878, and NA19240 (46-48). Out of ~3 million
SNVs, we were able to identify ~15 (range from 6 to 26) noncoding SNVs per individual
with high scores from FunSeq (>4), indicating their potential deleterious effects (Fig. 6E,
tables S9 and S10, and data S6 and S7). Thus, our approach can be used to prioritize
noncoding variants in personal genomes as well.
Discussion
We identified the sensitive and ultrasensitive noncoding elements, which exhibit depletion
of common polymorphisms and strong enrichment of known, inherited disease-causing
mutations. Because they cover a small fraction of the entire genome (comparable to the
exome), these regions can be probed alongside exome sequences in clinical studies. We
found that functionally disruptive noncoding mutations tend to be under strong selection: In
an analogous manner to LoF variants in coding genes, variants that break motifs in TF
binding sites are selected against. There is a close relation between connectivity in
biological networks and selective constraints: Higher connectivity is generally associated
with higher constraint. Furthermore, selection against indels and large SVs acts in a similar
fashion as against SNPs overall; however, the large size of SVs sometimes leads to a
complex relation with functional elements. On the basis of these patterns of negative
selection in functional elements, we developed a workflow and a corresponding software
tool to prioritize noncoding variants in disease studies.
The prioritization scheme presented in our paper can be readily extended by incorporation of
genomic polymorphisms from larger populations and higher-resolution functional
annotations. Moreover, with the availability of RNA-seq data from large cohorts, additional
genomic features such as eQTLs can be folded in. Our approach can be immediately applied
in precision medicine studies to prioritize noncoding variants for follow-up characterization,
particularly candidate driver mutations in cancer, and it can be further extended in the
future.
Materials and Methods
Details of all data sets and methods are provided in the supplementary materials. A brief
summary of major data sets and methods is provided here. SNPs, indels, and SVs from 1000
Genomes Phase I release were used to investigate patterns of selection in DNA elements
(24). Noncoding annotations were obtained from ENCODE Integrative paper release (2).
Although we did analyze broad functional annotations, such as all TFBSs, we focused on
highly specific categories such as distal binding sites of factor ZNF274. A randomization
procedure, similar to the Genome Structure Correction (2), was developed by considering
the dependency structure of different categories to deal with multiple hypothesis correction
while identifying the categories under significantly strong selection. Patterns of somatic
mutations were obtained from seven prostate cancer (17), three medulloblastoma (20), and
21 breast cancer genomes (19), whereas driver mutations were also identified in additional
57 prostate cancer genomes (18).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Fraction of rare (DAF < 0.5%) SNPs
(A) In various gene categories. Total number of SNPs in each category shown. (B) In
noncoding DHSs and coding genes, which show tissue-specific behavior. Matching tissues
for which both DHS and gene expression data are available shown in same colors: shades of
green for endodermal, gray for mesodermal, and blue for ectodermal origin of tissues. Red
dotted lines show the total fraction for all DHSs and coding genes. Asterisks show
significant depletion or enrichment after multiple-hypothesis correction. Error bars in both
(A) and (B) denote 95% binomial confidence intervals.
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Fig. 2. Fraction of rare SNPs in noncoding categories
Red dotted lines represent genomic average. Error bars denote 95% binomial confidence
intervals. Total numbers of SNPs in each category shown. (A) Broad categories.
Ultrasensitive and sensitive regions are those under very strong negative selection. TFSS,
sequence-specific TFs. Categories tested for enrichment of HighD sites (Fig. 5A) marked by
using hollow triangles on the left. (B) Example of high-resolution categories: TFBS motifs
separated into 15 families. e superscripts in red denote enrichment of eQTLs in TFBSs of
specific families. (C) Examples of TFBSs included in ultrasensitive category. (D) SNPs
breaking TF motifs show an excess of rare alleles compared with those conserving them.
Representative motifs for two families are shown. (E) Enrichment of HGMD regulatory
disease-causing mutations in ultrasensitive, sensitive, and annotated regions compared with
all noncoding regions. (F) SNPs not exhibiting allele-specific behavior (−) are enriched in
rare alleles compared with SNPs exhibiting allele-specific behavior (+).
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Fig. 3. SNPs in protein-protein interaction (PPI) network
(A) Degree centrality of coding-gene categories in PPI network. (B) Fraction of rare
missense SNPs at protein-interaction interfaces is higher than all rare missense SNPs (error
bars show 95% binomial confidence intervals; total number of SNPs also shown). (C)
Effects of SNVs at interaction interfaces on interactions of WASP with other proteins tested
by Y2H experiments. Wild-type (WT) WASP interacts with all proteins shown, whereas
each missense SNV disrupts its interaction with at least one protein.
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Fig. 4. Functional annotations of indels and SVs
(A) Fraction of rare indels in coding-gene categories. Total number of indels shown. (B)
Enrichment of SVs affecting functional annotations. Middle box shows genes, pseudogenes,
and TF motifs; upper blow-out shows gene parts in different modes, and bottom blow-out
shows enhancers with different formation mechanisms, i.e., NAHR, NH (nonhomologous),
TEI (transposable element insertion), and VNTR (variable number of tandem repeats).
Asterisks indicate significant enrichment (green) or depletion (red) after multiple hypothesis
correction. SVs intersecting various functional categories in different modes (e.g., whole/
partial) are shown in the right-hand schematics. (C) Aggregation of histone signal around
breakpoints of deletions formed by different mechanisms. Breakpoints centered at zero.
Aggregation for upstream and downstream regions corresponds to negative and positive
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distance, respectively. Signals for an activating histone mark (H3K4me1) and a repressive
mark (H3K27me3) are shown.
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Fig. 5. Functional implications of positive selection
(A) (Left) Frequency of HighD SNPs versus matched sites for broad categories (marked by
hollow triangles in Fig. 2A). (Right) Specific categories, e.g., specific TF families. Asterisk
denotes significant enrichment after multiple-hypothesis correction. e superscripts in red
denote the enrichment of eQTLs. (B) (Left) The in-degree of genes with HighD missense
SNPs is lower than that of all genes. (Center) The in-degree of genes with HighD SNPs in
their promoters is higher than all genes. (Right) The human regulatory network with edges
in gray. Red nodes represent genes with HighD SNPs in their promoters, and blue nodes
represent genes with HighD missense SNPs. Size of nodes scaled based on their degree
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centrality. Nodes with higher centrality are bigger and tend to be in the center, whereas those
with lower centrality are smaller and tend to be on the periphery.
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Fig. 6. Functional interpretation of disease variants
(A) Enrichment of functionally deleterious mutations among somatic compared with
germline SNVs. Mean values from seven prostate cancer samples shown (variation shown in
fig. S16). (B) Ratios for the number of SNVs that conserve versus break TF-binding motifs
depicted for NA12878, the average of 1000 Genomes Phase I samples,and the average of
somatic and germline samples from different cancers. Error bars represent 1 SD. MB,
medulloblastoma. (C) Filtering of somatic variants from a breast (PD4006, left) and a
prostate (PR-2832, right) cancer sample leading to identification of candidate drivers. (D) A
part of the FAM48A binding site sequenced by Sanger sequencing in an independent cohort
of 19 prostate cancer samples shown in green (with the coordinates of mutations observed in
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one sample). (E) Application of variants filtering scheme to Venter personal genome.
Number of SNVs in various categories shown.
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